Eli Lilly Halts Bimagrumab Obesity Trial Just Weeks After Initiation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 25 2025
0mins
Source: Benzinga
Eli Lilly Halts Bimagrumab Study: Eli Lilly & Co. has discontinued a mid-stage study of its experimental drug bimagrumab for obesity patients with type 2 diabetes, citing strategic business reasons, while a parallel study in non-diabetic patients continues.
Ongoing Competition in Obesity Treatment: The halted trial aimed to evaluate the efficacy and safety of bimagrumab and tirzepatide, amidst increasing competition in the obesity treatment market from companies like Novo Nordisk, Roche, and Regeneron.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like REGN with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REGN is 808.50 USD with a low forecast of 637.00 USD and a high forecast of 1057 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 749.440
Low
637.00
Averages
808.50
High
1057
Current: 749.440
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regeneron Pharmaceuticals Initiates Dividend Payments Amid Steady Growth
- Sales Growth Highlight: Regeneron Pharmaceuticals reported a 3% year-over-year sales increase in Q4 2025, with global net sales of DUPIXENT rising by 32%, showcasing strong performance in key products and reinforcing its market position.
- EYLEA HD Outstanding Performance: In the U.S. market, EYLEA HD sales surged by 66%, indicating robust momentum domestically and suggesting potential for continued growth in the future.
- Future Development Plans: The company anticipates at least four FDA approvals, including three new molecular entities, and plans to launch 18 additional Phase III clinical trials over the coming years, with total enrollment of about 35,000 patients to support the development of potential blockbuster products.
- Core Product Strategy: As a core pillar of the business, DUPIXENT is now used by over 1.4 million patients worldwide, indicating significant room for further growth and demonstrating Regeneron's strong competitive edge in the biopharmaceutical sector.
Continue Reading
McDonald Capital Increases Stake in FactSet Research Systems
- Stake Acquisition: McDonald Capital Investors disclosed a purchase of 86,891 shares of FactSet Research Systems during Q4, valued at approximately $24.39 million, indicating strong confidence in the company.
- Value Increase: Following the acquisition, McDonald Capital's position in FactSet rose to $53.90 million, an increase of $25.58 million from the previous quarter, reflecting both share additions and price appreciation.
- Portfolio Diversification: FactSet now represents 3.31% of McDonald Capital's portfolio, alongside other major holdings like Progressive and Regeneron, aligning with a long-term compounding investment strategy.
- Business Resilience: Despite a 45% decline in FactSet's stock price over the past year, the company continues to report organic revenue growth and strong free cash flow, underscoring the durability and sustainability of its business model.
Continue Reading